-
AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy
•
Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the US FDA for its early screening liquid biopsy product, AcornMed utLIFE-UC, designed for detecting urothelial carcinoma. Innovative Liquid Biopsy Technology for Urothelial Carcinoma DetectionThe AcornMed utLIFE-UC product leverages the company’s proprietary database and algorithms to…
